Click on the poster to request download
Potential First-In-Class Inhibitors of ERAP1, Generating Cancer Antigens As Novel Targets For MHCI-Directed Therapies.
First-on-class Inhibitors of ERAP1 Have The Potential To Be A Transformative Immunotherapy In Oncology.
First-in-class inhibitors of ERAP1 alter the immunopeptidome of cancer, driving a differentiated T cell response leading to tumor growth inhibition.
GRWD5769: A first-in-class Inhibitor of ERAP1, Generating Novel Cancer Antigens to Drive De Novo Anti-Tumor T Cell Responses.
First-in-Class Inhibitors of ERAP1 Alter the Immunopeptidome of Cancer, Driving a Differentiated T Cell Response Leading to Tumor Growth Inhibition. Poster exhibited at SITC 10-14 Nov, 2021.
First-in-class inhibitors of ERAP1 modify the tumor-specific surfaceome, driving a differentiated T cell response and tumor growth inhibition. Poster exhibited at the SITC Surfaceome Workshop 2021.
First-in-class inhibitors of ERAP1 have the potential to be a transformative immunotherapy in oncology. Poster exhibited at AACR 2021 (9-14 Apr, 2021).
Immunopeptidome changes mediated by a novel ERAP1 inhibitor leads to tumor growth inhibition. Poster exhibited at SITC 2020 (11-14 Nov, 2020).
Potent oral ERAP1 inhibitors modify the immunopeptidome in vivo and are novel immunotherapy agents. Poster exhibited at AACR 2020 (24-29 Apr, 2020).
Potent ERAP1 inhibitors modify the immunopeptidome and generate novel neoantigens. Poster exhibited at SITC 2019 (7-10 Nov, 2019).
The quickest way to access our posters is to click on the image above and complete the individual poster request form.
If you would like multiple posters, please complete the form below and we will come back to you shortly.